Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC55H60N8O12S |
InChIKeyNQLZSRAQWCFGSA-UHFFFAOYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Preclinical | United States | 09 Jul 2020 | |
EGFR-mutated non-small Cell Lung Cancer | Preclinical | United States | 09 Jul 2020 |